Investigators evaluated ctDNA as a prognostic marker for patients with follicular lymphoma in the phase III GALLIUM trial.

Circulating tumor DNA (ctDNA) can be detected in plasma samples sometimes several years prior to a clinical diagnosis of cancer, according to research ...

Desai, MBBS, MD, assistant professor of thoracic medical oncology/head and neck medical oncology at Fox Chase Cancer Center ...

SAN FRANCISCO — A blood test that measures circulating tumor DNA (ctDNA) can help to identify those patients with resectable colorectal cancer who are most likely to derive the most benefit from ...

Droplet digital PCR measurements of ctDNA may accurately identify patients with melanoma who are at high risk of recurrence. Patients who were ctDNA positive had worse recurrence-free and overall ...

ctDNA testing could help doctors track response, reduce unnecessary chemo, and identify relapse early for patients with aggressive B cell lymphomas. Dr. Hua-Jay Cherng, a hematologist oncologist at ...

Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan. This is an ASCO ...

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...

The nonsteroidal anti-inflammatory (NSAID) class of drugs, often used to treat pain and fever, includes medications like aspirin that have shown potential in CRC treatment. NSAIDs target ...

This transcript has been edited for clarity. Cheryl Lee, MD: Welcome to Medscape InDiscussion. I'm Dr Cheryl Lee. Today we'll be talking about circulating tumor DNA, or ctDNA, testing as the next step ...

Dr. W. Fraser Symmans explains how ctDNA is replacing CTCs to monitor breast cancer, detect mutations and track minimal residual disease At the CURE Educated Patient Breast Cancer Summit, held during ...